Food and Drug Administration (FDA)

North Carolina lawmakers propose Senate Bill 1018 to allocate $5.4 million for researching psychedelic medicines like psilocybin and MDMA to treat PTSD and depression in veterans, first responders, and trauma-impacted populations. The bill has bipartisan support and aligns with a federal executive order to fast-track FDA review of psychedelic therapies.

The House passed the agriculture, rural development, Food and Drug Administration (FDA), and related agencies appropriations bill as part of the fiscal 2027 funding process. The vote was 213-210, marking a key milestone for GOP leaders managing the government funding agenda.

A former adviser to President Trump during the COVID-19 pandemic stated that the U.S. is equipped to handle an Ebola outbreak. The adviser noted that the U.S. currently lacks confirmed heads for the CDC and FDA.

Dr. Deborah Birx, who led the 2014 Ebola response, assured that the CDC and FDA have a 'deep bench' of expertise to handle an Ebola outbreak despite lacking confirmed agency heads. Her comments were made during an appearance on 'Face the Nation with Margaret Brennan.'

FDA senior officials were unexpectedly informed of new guidelines allowing unauthorized e-cigarettes and nicotine pouches to enter the U.S. market without full regulatory vetting. The policy bypassed standard procedures and internal consultation with tobacco enforcement experts, sparking confusion about its authorization and implementation.

The Trump administration has pivoted on vaping, removing guardrails that limited the industry's growth and allowing unauthorized vapes to stay on the market. The administration granted marketing authorization to four flavored vaping products in two weeks. This move indicates the tobacco industry's influence over Washington.

Dr. Tracy Beth Høeg, former acting director of the FDA's Center for Drug Evaluation and Research, claimed she was fired, becoming the second high-ranking official to depart the FDA this week. Her departure follows that of former FDA Commissioner Dr. Marty Makary. Høeg will be replaced by her former deputy, Dr. Mike Davis.

Dr. Tracy Beth Høeg, former acting director of the FDA's Center for Drug Evaluation and Research, claimed she was fired, becoming the second high-ranking official to depart the FDA this week. Her departure follows that of former FDA Commissioner Dr. Marty Makary. Høeg will be replaced by her former deputy, Dr. Mike Davis.

Marty Makary resigned as FDA Commissioner, leaving a vacancy at the agency's top position. This comes after a year of significant changes, including an announcement about Covid-19 vaccine recommendations. The resignation follows a period of challenges for the agency's drug and biologics divisions.

Dr. Tracy Beth Hoeg, an FDA official, has been removed from her role leading the agency's drug program and will be replaced by Dr. Mike Davis. Hoeg was involved in scrutinizing the safety of COVID-19 vaccines and antidepressants. Her departure is the latest in an ongoing shake-up at the FDA.

The US is pressuring Germany to pay more for pharmaceuticals, while some US biotech companies consider moving trials outside the country due to FDA upheaval. The Trump administration is pushing for other countries to pay more for medications as the US pays less. This move may lead to delays in regulatory reviews and changes in traditional pathways for bringing new medicines to market.

The Supreme Court ruled that mifepristone, a drug used in medication abortion, can remain accessible via telehealth and mail. The decision reverses a previous order by the 5th Circuit Court of Appeals. The case was brought by the State of Louisiana, which claims that telehealth prescribing of mifepristone undermines its strict abortion ban.

The FDA's decision to withhold approval of a new skin cancer treatment has been met with criticism from doctors and patients, with some citing concerns about the agency's changed culture under Commissioner Marty Makary. The treatment, called RP1, had shown promise in prolonging the lives of some patients. The FDA's decision has raised questions about the agency's standards and processes.

Marty Makary's resignation from the FDA may alleviate some pressure, but the next head will face similar challenges, including political interference and funding cuts. The new chief will have to navigate these issues while balancing demands related to healthcare. Makary's departure is a result of his embattled tenure as a health leader in the Trump administration.

Robert F. Kennedy Jr.'s chief spokesperson, Rich Danker, resigned due to differences over e-cigarette flavors that could lead to child addiction. The resignation occurred a day after FDA Commissioner Marty made a related announcement. This development may impact Health and Human Services policies.

Gas prices are rising due to blockages in the Strait of Hormuz related to the unauthorized war in Iran, and there's a meeting with China's president. The FDA director stepped down over a disagreement on fruit-flavored vapes. Southern states are gerrymandering Black voters.

Marty Makary stepped down as FDA Commissioner due to pressure and rumors about his job security, with Kyle Diamantas taking over as the agency's top food regulator. President Trump acknowledged Makary's difficulties in the role. The transition occurs ahead of Trump's trip to China.

President Trump named Kyle Diamantas as acting FDA commissioner after Marty Makary's resignation. Diamantas is the Deputy FDA Commissioner for Food. Trump announced the change on Truth Social.

Marty Makary is stepping down as FDA Commissioner after a 13-month term marked by controversy and turmoil, and will be replaced by Kyle Diamantas as acting commissioner. The Trump administration will seek to fill three Senate-confirmed health positions. Makary's departure comes amid tensions with the White House and controversies over drug approvals.

Dr. Marty Makary, FDA commissioner, is resigning after a rocky tenure that drew complaints from health industry executives and anti-abortion activists. He struggled to manage the FDA's bureaucracy and failed to win the confidence of its staff. His resignation comes after just over a year leading the agency.

Marty Makary is resigning as FDA commissioner after one year, amid reports of President Trump's growing dissatisfaction. He will be replaced by Kyle Diamantas as acting director. The resignation announcement is expected on Tuesday.

FDA Commissioner Marty Makary is resigning due to mounting pressure from pro-life advocates and administration critics over his handling of high-profile FDA decisions. His resignation comes a day before he was set to testify in front of the Senate Appropriations Committee. Kyle Diamantis will serve as acting commissioner.

FDA Commissioner Marty Makary is resigning due to pressure from pro-life advocates and administration critics over his handling of high-profile FDA decisions. Health and Human Services Secretary Robert F. Kennedy Jr. pushed for Makary's resignation. Kyle Diamantis will serve as acting commissioner.

Marty Makary is resigning as FDA Commissioner and will be replaced by Kyle Diamantas as acting commissioner. President Donald Trump confirmed the resignation, stating that Makary is a great doctor who will do well. The change occurs amid turmoil at the FDA.

President Donald Trump downplayed reports of potentially firing FDA Commissioner Marty Makary, despite initial buzz about a possible ouster. Makary has been embroiled in controversies, including slow-walking a safety review for abortion pill mifepristone and facing opposition from pharmaceutical and biotech firms. Trump did not confirm the reports, telling reporters he knows nothing about it.

President Donald Trump downplayed reports of potentially firing FDA Commissioner Marty Makary, amid controversies and pressures from various groups. Makary has been under fire for his handling of flavored nicotine vapes and abortion pill mifepristone. Trump denied knowledge of the situation, sparking mixed reactions from pro-life activists and pharmaceutical firms.

California-based abortion pill suppliers are preparing backup plans in case the Supreme Court restricts access to mifepristone. The Supreme Court has a deadline of May 11 to make a decision, and California suppliers are already pivoting to alternative abortion drugs. Mifepristone is used in nearly two-thirds of all U.S. abortions.

California-based abortion pill suppliers are preparing backup plans in case the Supreme Court restricts access to mifepristone. The Supreme Court is considering a decision that could limit mailing of the drug, with a deadline of May 11. Suppliers are pivoting to alternative abortion drugs, including misoprostol.

President Trump plans to fire FDA Commissioner Marty Makary, according to several media reports, after a tumultuous year for the FDA. The plan is not final and could change. The administration has not decided who would serve as acting director upon Makary's departure.

Trump has signed off on a plan to fire FDA Commissioner Marty Makary, indicating a significant change in leadership at the FDA. The move is expected to have implications for the agency's regulatory decisions. Trump's decision may impact the FDA's approach to various issues

Prominent Covid-era ivermectin advocates are promoting the drug as a potential treatment for hantavirus despite lack of clinical evidence. The Andes hantavirus outbreak has sparked concerns and misinformation about ivermectin's effectiveness. Health experts emphasize that there is no meaningful clinical evidence supporting ivermectin's use against hantaviruses.

President Donald Trump has shifted his AI policy from a hands-off approach to one of strict regulation, considering requiring high-risk AI models to undergo government review before use. This change comes after Trump initially tore up Biden's Executive Order 14110, which demanded safe and secure AI. The new approach aims to address escalating cybersecurity and national-security risks.

President Donald Trump has announced initiatives to reduce prescription drug costs, but the impact is uncertain and many prices have increased. Americans pay about three times as much as people in other countries for the same drugs. The effectiveness of Trump's efforts remains to be seen.

RFK Jr. has cleared the path for minors to use tanning beds, despite a proposed FDA rule intended to protect children from indoor tanning, which increases melanoma risk by 75%. This decision has been met with dismay from dermatologists. The removal of the proposed rule may put children at greater risk.

Gen Z and Gen Alpha are driving a shift in snack preferences, favoring simpler ingredients and more nutritional benefits, leading to a major shake-up in the grocery industry. Thirty-five percent of parents prioritize natural ingredients, while 34% seek high-protein options. This change is pushing brands to rethink their ingredients and marketing tactics.

A federal appeals court blocked the mailing of the abortion pill mifepristone under current FDA rules, requiring in-person prescriptions and likely sparking a Supreme Court battle. The 5th U.S. Circuit Court of Appeals decision restores pre-pandemic safety protocols, citing concerns over adverse event reporting and state authority, while critics warn it will limit abortion access nationwide.

A federal appeals court blocked the mailing of the abortion pill mifepristone under FDA rules, citing safety concerns and state authority, with a nationwide effect. The ruling requires in-person prescriptions for mifepristone, reversing pandemic-era changes, and sets up a potential Supreme Court challenge over abortion access.

The FDA announced ultra-fast review timelines for three psychedelic drugs, including psilocybin and methylone, following an executive order by the Trump administration to accelerate access to psychedelics for mental health treatments. The move aligns with growing support from Trump allies and Health Secretary Robert F. Kennedy Jr.'s advocacy for psychedelic therapies.

The co-hosts of ABC’s 'The View' criticized HHS Secretary Robert F. Kennedy Jr. for his leadership, citing his lack of medical credentials and controversial policies. Joy Behar accused the administration of pursuing policies 'trying to kill us,' while Alyssa Farah Griffin highlighted concerns over cutting $500 million in mRNA vaccine research funding. Kennedy faced scrutiny for his AI-driven healthcare vision and past controversies, including addiction and risky behavior.

RFK Jr. advocates for loosening federal restrictions on peptides, potentially boosting telehealth companies, compounding pharmacies, and longevity clinics. The FDA will review peptide regulations in July, while experts debate their efficacy and safety, with market projections reaching $180 billion in five years.